Mayne Banks On Nextstellis As Generics Business Suffers

Company Sees 6% Decline In Revenues But Dermatology Portfolio Continues To Grow

Progress
Mayne anticipates growing in the next half on the back of new launches • Source: Alamy

More from Earnings

More from Business